Physicochemical characterization of dipeptidyl peptidase-4 inhibitor alogliptin in physical mixtures with excipients

被引:0
|
作者
Charise Dallazem Bertol
Rafael Nicolay Pereira
Cassiana Mendes
Amarilis Scremim Paulino
Marcos Antônio Segatto Silva
Pedro Eduardo Froehlich
机构
[1] Universidade de Passo Fundo,Curso de Farmácia, Instituto de Ciências Biológicas
[2] Universidade Federal do Rio Grande do Sul,Programa de Pós
[3] Universidade Federal de Santa Catarina,graduação em Ciências Farmacêuticas, Laboratório de Produção de Substâncias Químicas de Referência
关键词
Alogliptin; Compatibility studies; Crystallinity; Thermoanalysis;
D O I
暂无
中图分类号
学科分类号
摘要
Alogliptin (ALG) is a hypoglycemic drug used in diabetes which inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), preventing the degradation of incretins, stimulating insulin secretion. The physicochemical characteristics of ALG were evaluated by differential scanning calorimetry (DSC), thermogravimetry (TG) and scanning electron microscopy equipped with energy-dispersive X-ray spectrometer (SEM/EDS). The compatibility studies were carried out between ALG and excipients (physical mixtures, 1:1) using DSC, TG, diffuse reflectance Fourier transform infrared spectroscopy (FTIR), X-ray powder diffraction (XRPD) and hot-stage microscopy. ALG presented purity near to 99%, melted in the range of 179.4–187.2 °C, followed by decomposition which started in 198.0 °C. SEM/EMS analysis of ALG presented irregular crystals and traces of impurities as copper and lead. DSC investigations obtained by physical mixtures showed minor alterations in the melting ranges of ALG with mannitol, magnesium stearate and commercial tablets. Solubilization of ALG in the fused excipient was observed by hot-stage microscopy between mannitol and ALG, and in tablets. The interaction observed in the mixture with magnesium stearate is due to the melting of the excipient and drug separately, first the excipient and then the drug. FTIR showed additional bands related to the excipients. XRPD proved that ALG has a crystal form and no alterations in the ALG profile were observed after the mixtures. ALG was compatible with all excipients tested. These results were important to understand the characteristics, stability and compatibility of the drug, and proved to be useful in preformulation studies.
引用
收藏
页码:1575 / 1584
页数:9
相关论文
共 50 条
  • [1] Physicochemical characterization of dipeptidyl peptidase-4 inhibitor alogliptin in physical mixtures with excipients
    Bertol, Charise Dallazem
    Pereira, Rafael Nicolay
    Mendes, Cassiana
    Paulino, Amarilis Scremim
    Segatto Silva, Marcos Antonio
    Froehlich, Pedro Eduardo
    JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2017, 130 (03) : 1575 - 1584
  • [2] Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits
    Yamamoto, Toshihiko
    Shimano, Masayuki
    Inden, Yasuya
    Takefuji, Mikito
    Yanagisawa, Satoshi
    Yoshida, Naoki
    Tsuji, Yukiomi
    Hirai, Makoto
    Murohara, Toyoaki
    HEART RHYTHM, 2015, 12 (06) : 1362 - 1369
  • [3] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
  • [4] A dipeptidyl peptidase-4 inhibitor, alogliptin, improves postprandial triglycemia and postprandial endothelial dysfunction
    Noda, Y.
    Miyoshi, T.
    Oe, H.
    Ohno, Y.
    Nakamura, K.
    Morita, H.
    Kohno, K.
    Toh, T.
    Kusano, K.
    Ito, H.
    EUROPEAN HEART JOURNAL, 2012, 33 : 886 - 886
  • [5] Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties
    Kutoh, Eiji
    Kaneoka, Noriko
    Hirate, Mitsuru
    ENDOCRINE RESEARCH, 2015, 40 (02) : 88 - 96
  • [6] Lack of dermal toxicity with the highly selective dipeptidyl peptidase-4 inhibitor alogliptin in monkeys
    Sato, Keiichiro
    Ozaki, Harushige
    Salamon, Clare M.
    Christopher, Ronald J.
    Yamamoto, Masaki
    DIABETES, 2008, 57 : A580 - A580
  • [7] Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
    Ndefo, Uche Anadu
    Okoli, Okwuchukwu
    Erowele, Goldina
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (02) : 103 - 109
  • [8] Dipeptidyl peptidase-4 inhibitor approaches
    Bloomgarden, Zachary
    JOURNAL OF DIABETES, 2017, 9 (01) : 5 - 7
  • [9] Research strategy for alogliptin, a dipeptidyl peptidase-4 inhibitor, as a novel anti-diabetic agent
    Matsuo, Takanori
    Takeuchi, Koji
    Yamada, Yukio
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 41P - 41P
  • [10] Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment
    Karim, Aziz
    Fleck, Penny
    Hetman, Laura
    Marbury, Thomas
    Ravis, William R.
    Cannon, Courtney
    Zhang, Wen-Can
    Mekki, Qais
    DIABETES, 2008, 57 : A160 - A160